SCHEMBL4384916

SCHEMBL4384916

Nc1ccc(CS(=O)(=O)N2CCC(=NOCc3cccc(C(F)(F)F)c3)CC2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 5/20 0.46
IDO1 P14902 2/20 0.40
SMN1; SMN2 Q16637 3/20 0.39
CYP2C19 P33261 2/20 0.39
LMNA P02545 3/20 0.39
ALDH1A1 P00352 2/20 0.38
MAPT P10636 2/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
TSHR P16473 1/20 0.38
NFKB1 P19838 1/20 0.38
MAPK1 P28482 1/20 0.38
THPO P40225 1/20 0.38
MTOR P42345 1/20 0.38
BLM P54132 1/20 0.38
PMP22 Q01453 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
GPR142 Q7Z601 1/20 0.38
HTT P42858 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4387475 0.87 LMNA (0.51) MAOBIDO1SMN1; SMN2LMNAALDH1A1
Hydrochloric Acid SCHEMBL4383806 0.86 LMNA (0.51) MAOBIDO1SMN1; SMN2LMNAALDH1A1
SCHEMBL4382720 0.82 LMNA (0.47) MAOBSMN1; SMN2LMNAALDH1A1MAPT
SCHEMBL4382904 0.82 LMNA (0.45) MAOBIDO1SMN1; SMN2CYP2C19LMNA
SCHEMBL4385367 0.81 HTT (0.51) SMN1; SMN2LMNAALDH1A1MAPTHTT
SCHEMBL4385214 0.80 LMNA (0.45) MAOBIDO1SMN1; SMN2CYP2C19LMNA
SCHEMBL4379552 0.80 LMNA (0.52) SMN1; SMN2LMNAALDH1A1MAPTHTT
SCHEMBL4391011 0.80 LMNA (0.54) SMN1; SMN2LMNAALDH1A1MAPTHTT
SCHEMBL4379445 0.80 LMNA (0.41) MAOBIDO1SMN1; SMN2CYP2C19LMNA
SCHEMBL4386335 0.78 TRPV4 (0.42) SMN1; SMN2LMNAALDH1A1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090298878-A1 OXIME COMPOUNDS AND THE USE THEREOF PURDUE PHARMA L.P. 2009-12-03 US disclosed
US-20090298878-A1 OXIME COMPOUNDS AND THE USE THEREOF PURDUE PHARMA L.P. 2009-12-03 US disclosed
US-20090298878-A1 OXIME COMPOUNDS AND THE USE THEREOF PURDUE PHARMA L.P. 2009-12-03 US disclosed
EP-2040698-A2 OXIME COMPOUNDS AND THE USE THEREOF SHIONOGI & CO., LTD. (JP) 2009-04-01 EP disclosed
WO-2008008398-A2 OXIME COMPOUNDS AND THE USE THEREOF SHIONOGI & CO., LTD. (JP) 2008-01-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090298878-A1 OXIME COMPOUNDS AND THE USE THEREOF KCNN4, CACNA1A, KCNN3 MAOB 534/4885IDO1 305/4885SMN1; SMN2 664/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.